Antenatal Diagnosis and Treatment in Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency and Congenital Adrenal Hyperplasia Screening in Newborns.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic data synthesis
PubMed 39713885 · doi:10.4274/jcrpe.galenos.2024.2024-6-10-S
What was done
This narrative review synthesizes clinical approaches and current guideline perspectives regarding antenatal diagnosis, prenatal steroid treatment, and universal newborn screening for congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21-OHD).
What was found
The abstract provides no empirical data, odds ratios, or statistical metrics from original investigations. It notes the Mendelian inheritance ratio (a 1 in 8 probability of having an affected female fetus per pregnancy in carrier couples). It highlights that antenatal corticosteroid therapy to prevent female external genital virilization is categorized as experimental and controversial in recent clinical guidelines due to safety concerns, warranting restriction to specialized research centers. Postnatally, newborn screening for 21-OHD is reported to effectively detect severe salt-wasting forms, reduce early infant mortality, and assist in correct sex assignment.
Why it matters
The review underscores the current clinical consensus cautioning against routine antenatal steroid use outside specialized centers while reinforcing the critical life-saving utility of universal newborn screening for classic CAH.
Limits
As a narrative review, it lacks a systematic search strategy, formal risk of bias assessment, or quantitative data synthesis. Specific adverse event rates, efficacy estimates, and sample sizes are not reported in the abstract.